Phitech

PhiTech is a high-tech bioinformatics company that leverages Artificial Intelligence and multi-omics data integration to revolutionize the diagnosis and treatment of rare diseases and hereditary cancers. By bridging the gap between genomics and transcriptomics, PhiTech provides clinicians and researchers with the tools needed to make precision medicine faster, more accurate, and more accessible.

Key Capabilities

• G&M Flagship Platform: An AI-powered diagnostic decision support system that integrates Whole Exome/Genome Sequencing (WES/WGS) with RNA-Seq data. This "multi-omics" approach allows for a comprehensive look at genetic variants and their functional impacts.

• Proprietary AI Prioritization: PhiTech uses a custom AI algorithm to automatically prioritize disease-causing genes. This reduces the time required for manual analysis and significantly improves diagnostic yield—by up to 30% compared to traditional methods.

• Transcriptomic Insights: The platform identifies aberrant splicing events, abnormal gene expressions, and allele-specific variations across multiple tissue types, providing deeper functional evidence than DNA sequencing alone.

• Scalable Clinical Solutions: Designed for diagnostic laboratories, hospitals, and clinics, the platform accelerates variant interpretation, helping patients who often face a "diagnostic odyssey" lasting over six years.

• Biopharma & Research Support: Beyond diagnostics, PhiTech partners with academic centers and biopharma companies to optimize drug development through precise biomarker identification and efficient patient stratification.

Strategic Value

PhiTech addresses a critical global challenge: over 400 million people live with rare diseases, yet 60% remain undiagnosed. By automating the most complex parts of genetic interpretation and providing functional RNA evidence, PhiTech acts as a force multiplier for geneticists and oncologists. Recently featured in Forbes Turkey’s "Girişim 2026" and a graduate of the Alchemist Accelerator, PhiTech is positioned as a leader in the next generation of AI-driven healthcare.